middle.news
How Immuron’s FDA Nod and Record Sales Could Reshape Its Future
7:02pm on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
How Immuron’s FDA Nod and Record Sales Could Reshape Its Future
7:02pm on Wednesday 25th of February, 2026 AEDT
Key Points
Half-year loss reduced by 23% to A$1.92 million
Revenue up 4.8% to A$4.18 million driven by Travelan sales
FDA approves IMM-529 IND for Phase 2 trial targeting C. difficile
US Department of Defense funds new oral therapeutics development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMMURON (ASX:IMC)
OPEN ARTICLE